Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation Indian Medical PG Practice Questions and MCQs

Question 141: Heparin acts by activation of which substance?

A. Plasmin
B. TPA (Tissue Plasminogen Activator)
C. Antithrombin III (Correct Answer)
D. Fibrinolysin

Explanation: ### Explanation **Mechanism of Action (Why C is correct):** Heparin is an indirect-acting anticoagulant. It works by binding to **Antithrombin III (AT-III)**, a natural plasma protease inhibitor. This binding induces a conformational change in AT-III, accelerating its activity by nearly 1,000-fold. The Heparin-AT-III complex then inactivates several clotting factors, most notably **Thrombin (Factor IIa)** and **Factor Xa**, as well as factors IXa, XIa, and XIIa. By neutralizing these factors, heparin prevents the conversion of fibrinogen to fibrin, thereby inhibiting clot formation. **Analysis of Incorrect Options:** * **A & D (Plasmin/Fibrinolysin):** These are synonymous terms for the enzyme responsible for degrading existing fibrin clots. Heparin prevents *clot formation* (anticoagulant) but does not dissolve *existing clots* (thrombolytic). * **B (TPA):** Tissue Plasminogen Activator is a thrombolytic agent used to convert plasminogen into plasmin. It is used in acute MI or stroke, whereas heparin is used for prophylaxis or to prevent further propagation of a thrombus. **NEET-PG High-Yield Pearls:** * **Monitoring:** The efficacy of Unfractionated Heparin (UFH) is monitored using **aPTT** (intrinsic pathway). Low Molecular Weight Heparin (LMWH) usually does not require monitoring but can be checked using **Factor Xa levels**. * **Antidote:** The specific antidote for heparin overdose is **Protamine Sulfate** (a basic drug that neutralizes acidic heparin via ion pairing). * **Side Effects:** The most unique side effect is **Heparin-Induced Thrombocytopenia (HIT)**, caused by antibodies against the Heparin-Platelet Factor 4 complex. * **LMWH vs. UFH:** LMWH (e.g., Enoxaparin) mainly inactivates Factor Xa and has better bioavailability and a longer half-life compared to UFH.

Question 142: A patient is taking aspirin. What is the expected laboratory finding?

A. Prolonged bleeding time (BT) (Correct Answer)
B. Prolonged prothrombin time (PT)
C. Prolonged activated partial thromboplastin time (APTT)
D. Prolonged clotting time (CT)

Explanation: **Explanation:**1. Why Option A is Correct:Aspirin is an irreversible inhibitor of the enzyme **Cyclooxygenase-1 (COX-1)**. By acetylating the active site of COX-1 in platelets, it prevents the synthesis of **Thromboxane A2 (TXA2)**, a potent platelet aggregator and vasoconstrictor. [1, 3] Since platelets are anucleated and cannot synthesize new enzymes, this effect lasts for the entire lifespan of the platelet (approx. 7–10 days). [1, 3] **Bleeding Time (BT)** is a clinical measure of platelet function and primary hemostasis; therefore, inhibiting platelet aggregation directly leads to a prolonged BT. [1, 2]2. Why Other Options are Incorrect:* **Options B & C (PT and APTT):** These tests measure the integrity of the coagulation cascade (secondary hemostasis). PT assesses the extrinsic/common pathways, while APTT assesses the intrinsic/common pathways. Aspirin affects platelet aggregation, not the synthesis or activity of clotting factors.* **Option D (Clotting Time):** Clotting time is a crude measure of the coagulation cascade (specifically the intrinsic pathway). It remains normal in patients taking antiplatelet drugs like aspirin because the fibrin formation process is unaffected.3. High-Yield Clinical Pearls for NEET-PG:* **Low-dose Aspirin (75–150 mg):** Selective for COX-1 (Antiplatelet effect). [3]* **High-dose Aspirin:** Inhibits both COX-1 and COX-2 (Anti-inflammatory effect). [3]* **Surgery Protocol:** Aspirin should ideally be stopped **7 days prior** to major surgery to allow for the generation of new, functional platelets. [1, 3]* **Differentiate:** While Aspirin increases BT, [1] **Warfarin** increases PT/INR, and **Heparin** increases APTT.

Question 143: Aspirin's antiplatelet action is primarily due to which mechanism?

A. Decreased synthesis of thromboxane A2 (Correct Answer)
B. Inhibition of GPIIb/IIIa receptors
C. Inhibition of adenylyl cyclase
D. None of the above

Explanation: **Explanation:** **Mechanism of Action (Why A is correct):** Aspirin (Acetylsalicylic acid) acts by **irreversibly inhibiting the enzyme Cyclooxygenase-1 (COX-1)** via acetylation of a serine residue. In platelets, COX-1 is responsible for converting arachidonic acid into **Thromboxane A2 (TXA2)**. TXA2 is a potent vasoconstrictor and a key mediator of platelet aggregation. Because platelets are anucleated and cannot synthesize new enzymes, the inhibition lasts for the entire lifespan of the platelet (approx. 7–10 days). **Analysis of Incorrect Options:** * **B. Inhibition of GPIIb/IIIa receptors:** This is the mechanism of drugs like **Abciximab, Eptifibatide, and Tirofiban**. These drugs block the "final common pathway" of platelet aggregation by preventing fibrinogen binding. * **C. Inhibition of adenylyl cyclase:** This is incorrect. Drugs like **P2Y12 inhibitors (Clopidogrel, Prasugrel)** prevent the inhibition of adenylyl cyclase by blocking ADP receptors, thereby maintaining high cAMP levels which inhibit platelet activation. **High-Yield Clinical Pearls for NEET-PG:** * **Low-dose Aspirin (75–150 mg):** Selectively inhibits TXA2 without significantly affecting Prostacyclin (PGI2) synthesis in endothelial cells (as endothelial cells can regenerate COX). * **Primary/Secondary Prevention:** Used in Myocardial Infarction (MI) and Ischemic Stroke. * **Side Effects:** Gastric GI bleed (most common) and Reye’s syndrome (in children with viral infections). * **Surgery Protocol:** Aspirin should ideally be stopped **7 days prior** to major elective surgery to allow for new platelet formation.

Question 144: Parenteral Iron therapy is indicated only when:

A. Oral Iron intolerance (Correct Answer)
B. Pregnancy with Hemoglobin less than 8 g/dL
C. Postpartum period with Anemia
D. Emergency surgery suspected of severe blood loss

Explanation: ### Explanation **1. Why Oral Iron Intolerance is Correct:** The primary indication for parenteral iron therapy is the inability to tolerate or absorb oral iron. Oral iron is the first-line treatment for Iron Deficiency Anemia (IDA) due to its safety and low cost. However, many patients experience significant gastrointestinal side effects (nausea, epigastric pain, constipation). Parenteral iron is indicated in cases of **absolute intolerance**, malabsorption syndromes (e.g., Celiac disease, IBD), or when rapid replenishment is required in patients with chronic kidney disease (CKD) on erythropoietin. **2. Analysis of Incorrect Options:** * **Option B (Pregnancy < 8 g/dL):** While severe anemia in pregnancy requires management, oral iron is still the initial choice unless it is the third trimester or there is intolerance. Parenteral iron is generally avoided in the first trimester. * **Option C (Postpartum Anemia):** Postpartum anemia is usually managed with oral iron unless the patient is hemodynamically unstable or has severe symptoms, in which case blood transfusion or parenteral iron might be considered, but it is not a primary indication. * **Option D (Emergency Surgery):** In emergency scenarios with severe blood loss, iron therapy (oral or parenteral) is too slow to act. The immediate management is **Blood Transfusion** to restore oxygen-carrying capacity and volume. **3. High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Oral Ferrous Sulfate is the standard. * **Parenteral Preparations:** Iron Dextran (highest risk of anaphylaxis; requires a test dose), Iron Sucrose, and Ferric Carboxymaltose (preferred for rapid total dose infusion). * **Side Effects:** The most common side effect of IV iron is a metallic taste; the most serious is anaphylaxis. * **Contraindication:** Never give parenteral iron to a patient with active systemic infection, as iron can promote bacterial growth.

Question 145: Which of the following anticoagulants can be used both in vivo and in vitro?

A. Heparin (Correct Answer)
B. Warfarin
C. Oxalates
D. EDTA

Explanation: **Explanation:** The classification of anticoagulants based on their site of action is a high-yield topic for NEET-PG. Anticoagulants are categorized into those that act **in vivo** (inside the body), **in vitro** (outside the body, e.g., in blood vials), or **both**. **1. Why Heparin is the Correct Answer:** Heparin is a rapid-acting indirect thrombin inhibitor. It works by activating **Antithrombin III**, which then inactivates Thrombin (Factor IIa) and Factor Xa. Since Antithrombin III is naturally present in the plasma, Heparin can exert its anticoagulant effect both when injected into a patient (**in vivo**) and when added to a test tube containing collected blood (**in vitro**). **2. Analysis of Incorrect Options:** * **Warfarin (Option B):** It is an oral anticoagulant that acts as a Vitamin K epoxide reductase (VKOR) inhibitor. It works by preventing the hepatic synthesis of clotting factors II, VII, IX, and X. Because it requires a functioning liver to exert its effect, it is active **only in vivo**. * **Oxalates (Option C) and EDTA (Option D):** These are calcium chelators. They remove calcium ions (Factor IV) from the blood, which is essential for the coagulation cascade. While highly effective for laboratory samples, they cannot be used in vivo because systemic chelation of calcium would lead to fatal hypocalcemia (tetany and cardiac arrest). Thus, they are used **only in vitro**. **Clinical Pearls for NEET-PG:** * **Drug of choice in pregnancy:** Heparin (does not cross the placenta). * **Monitoring:** Heparin is monitored via **aPTT**, while Warfarin is monitored via **PT/INR**. * **Antidotes:** Protamine sulfate for Heparin; Vitamin K or Fresh Frozen Plasma (FFP) for Warfarin. * **EDTA:** Preferred anticoagulant for hematological investigations (CBC) as it preserves blood cell morphology.

Question 146: Warfarin acts by inhibiting the activation of all the following factors except:

A. Factor III (Correct Answer)
B. Factor VII
C. Factor IX
D. Factor X

Explanation: **Explanation:** Warfarin is an oral anticoagulant that acts as a **Vitamin K antagonist**. It inhibits the enzyme **Vitamin K Epoxide Reductase (VKOR)**, which is responsible for regenerating the reduced form of Vitamin K. Reduced Vitamin K is a mandatory cofactor for the enzyme **$\gamma$-glutamyl carboxylase**, which performs the post-translational modification (carboxylation) of specific glutamate residues on certain clotting factors. **Why Factor III is the correct answer:** Factor III, also known as **Tissue Factor (Thromboplastin)**, is a cell surface glycoprotein found in subendothelial tissue. It is not synthesized in the liver and does not require Vitamin K for its activation or function. Therefore, Warfarin has no effect on Factor III. **Why the other options are incorrect:** Warfarin specifically inhibits the synthesis of functional Vitamin K-dependent clotting factors, which include: * **Factor VII (Option B):** Part of the extrinsic pathway; it has the shortest half-life (~6 hours) and is the first to be depleted. * **Factor IX (Option C):** Part of the intrinsic pathway. * **Factor X (Option D):** Part of the common pathway. * **Factor II (Prothrombin):** Part of the common pathway. * **Proteins C and S:** Endogenous anticoagulants that are also Vitamin K-dependent. **High-Yield Clinical Pearls for NEET-PG:** * **Monitoring:** Warfarin therapy is monitored using **PT (Prothrombin Time)** and **INR (International Normalized Ratio)**. * **Warfarin-Induced Skin Necrosis:** Occurs due to the rapid depletion of Protein C (short half-life), leading to a transient hypercoagulable state. This is why "heparin bridging" is required. * **Teratogenicity:** Warfarin is contraindicated in pregnancy as it crosses the placenta, causing **Fetal Warfarin Syndrome** (chondrodysplasia punctata, nasal hypoplasia). * **Antidote:** For immediate reversal, use **Fresh Frozen Plasma (FFP)** or Prothrombin Complex Concentrate (PCC). For non-emergency reversal, use **Vitamin K1 (Phytonadione)**.

Question 147: Which of the following drugs is used in sickle cell anemia?

A. Hydroxyurea (Correct Answer)
B. Carmustine
C. Paclitaxel
D. Bleomycin

Explanation: **Explanation:** **Hydroxyurea** is the drug of choice for the prevention of painful vaso-occlusive crises in patients with sickle cell anemia. Its primary mechanism of action involves the **induction of Fetal Hemoglobin (HbF)** synthesis. HbF inhibits the polymerization of deoxygenated Hemoglobin S (HbS), thereby preventing the sickling of red blood cells, reducing hemolysis, and improving microvascular blood flow. Additionally, it reduces the expression of adhesion molecules on neutrophils and reticulocytes, further decreasing vascular occlusion. **Analysis of Incorrect Options:** * **Carmustine (BCNU):** A nitrosourea alkylating agent used primarily in the treatment of brain tumors (due to its ability to cross the blood-brain barrier) and lymphomas. It has no role in hemoglobin modulation. * **Paclitaxel:** A microtubule stabilizer (taxane) used in the treatment of ovarian, breast, and lung cancers. It acts by inhibiting mitosis, not by affecting erythropoiesis. * **Bleomycin:** An antitumor antibiotic that causes DNA strand breaks. It is used in Hodgkin lymphoma and testicular cancer but is notoriously associated with pulmonary fibrosis. **High-Yield NEET-PG Pearls:** * **Mechanism:** Hydroxyurea inhibits the enzyme **Ribonucleotide Reductase**, which converts ribonucleotides to deoxyribonucleotides (S-phase specific). * **Other Indications:** Chronic Myeloid Leukemia (CML), Polycythemia Vera, and Essential Thrombocythemia. * **Side Effects:** The dose-limiting toxicity is **bone marrow suppression** (leukopenia, anemia, thrombocytopenia). It is also potentially teratogenic. * **Other drugs in Sickle Cell:** **Voxelotor** (prevents HbS polymerization by increasing oxygen affinity) and **Crizanlizumab** (P-selectin inhibitor).

Question 148: Blood level of which clotting factor declines most rapidly after the initiation of warfarin therapy?

A. Factor X
B. Prothrombin
C. Factor VII (Correct Answer)
D. Factor IX

Explanation: **Explanation:** Warfarin acts as a competitive inhibitor of the enzyme **Vitamin K Epoxide Reductase (VKOR)** [4]. This inhibition prevents the γ-carboxylation of glutamate residues on Vitamin K-dependent clotting factors (**II, VII, IX, and X**) and anticoagulant proteins (C and S), rendering them inactive [3]. The clinical effect of warfarin is not immediate; it depends on the **half-life** of the clotting factors already circulating in the plasma [1]. The factor with the shortest half-life will be depleted first. 1. **Factor VII (Correct):** It has the shortest half-life (approximately **4–6 hours**) [1]. Therefore, its levels decline most rapidly after starting warfarin, leading to an initial prolongation of the Prothrombin Time (PT/INR). 2. **Factor IX (Incorrect):** It has an intermediate half-life of approximately 24 hours [1]. 3. **Factor X (Incorrect):** It has an intermediate half-life of approximately 36–48 hours [1]. 4. **Prothrombin/Factor II (Incorrect):** It has the longest half-life (approximately **60–72 hours**) and is the last to decline [1]. **High-Yield Clinical Pearls for NEET-PG:** * **The "C" before "II" Rule:** Protein C also has a very short half-life (~8 hours) [2]. Because Protein C (an anticoagulant) disappears faster than Factors II and X (procoagulants), a temporary **hypercoagulable state** occurs. This is why "Heparin bridging" is mandatory to prevent **Warfarin-induced skin necrosis**. * **Monitoring:** Warfarin therapy is monitored using **PT/INR** (extrinsic pathway), while Heparin is monitored using **aPTT** (intrinsic pathway). * **Antidote:** For immediate reversal of warfarin, use **Fresh Frozen Plasma (FFP)** or Prothrombin Complex Concentrate (PCC). For non-emergent reversal, use **Vitamin K1 (Phytonadione)**.

Question 149: G-CSF is used in the treatment of which condition?

A. Anemia
B. Neutropenia (Correct Answer)
C. Malaria
D. Filariasis

Explanation: Granulocyte Colony-Stimulating Factor (G-CSF), such as Filgrastim and Pegfilgrastim, is a glycoprotein that stimulates the bone marrow to produce granulocytes (primarily neutrophils) and stem cells [1].1. Why Neutropenia is Correct: G-CSF acts on specific receptors on myeloid progenitor cells to stimulate their proliferation, differentiation, and activation. It is the treatment of choice for chemotherapy-induced neutropenia, as it reduces the duration and severity of the condition, thereby preventing life-threatening opportunistic infections (Febrile Neutropenia) [1, 2]. It is also used in harvesting peripheral blood stem cells for autologous transplantation [1, 2].2. Why Other Options are Incorrect: Anemia: This is a deficiency of red blood cells or hemoglobin. It is treated with Erythropoietin (EPO), Iron, Vitamin B12, or Folic acid, depending on the etiology. Malaria: A protozoal infection treated with antimalarials like Chloroquine, Artemisinin-based combination therapy (ACT), or Quinine. Filariasis: A parasitic disease caused by nematodes, treated with Diethylcarbamazine (DEC) or Ivermectin.High-Yield Clinical Pearls for NEET-PG: Side Effects: The most common side effect of G-CSF is bone pain (due to marrow expansion). GM-CSF (Sargramostim): Unlike G-CSF, GM-CSF stimulates multiple lineages (neutrophils, eosinophils, and monocytes) but is associated with more side effects like fever and edema [1, 2]. Timing: G-CSF should not be administered within 24 hours of chemotherapy as it may worsen myelosuppression by stimulating rapidly dividing cells.

Question 150: Which drug binds to and inhibits the Gp IIb/IIIa glycoprotein, thereby causing platelet antiaggregatory effects?

A. Clopidogrel
B. Enoxaparin
C. Fondaparinux
D. Tirofiban (Correct Answer)

Explanation: **Explanation:** **Correct Option: D. Tirofiban** The final common pathway of platelet aggregation involves the activation of the **Glycoprotein (Gp) IIb/IIIa receptor**. Once activated, this receptor binds to fibrinogen, which acts as a bridge between adjacent platelets. **Tirofiban** (along with Eptifibatide and Abciximab) is a specific Gp IIb/IIIa inhibitor. By binding to this receptor, it prevents fibrinogen cross-linking, thereby exerting a potent antiaggregatory effect. It is primarily used in Acute Coronary Syndromes (ACS) and during Percutaneous Coronary Intervention (PCI). **Incorrect Options:** * **A. Clopidogrel:** This is a P2Y12 receptor antagonist. It works by inhibiting the ADP-mediated pathway of platelet activation, not the Gp IIb/IIIa receptor directly. * **B. Enoxaparin:** This is a Low Molecular Weight Heparin (LMWH). It acts as an anticoagulant by accelerating the inhibition of Factor Xa (and to a lesser extent, Factor IIa) by antithrombin III. * **C. Fondaparinux:** This is a synthetic pentasaccharide that acts as a selective Factor Xa inhibitor. It has no direct effect on platelet receptors. **NEET-PG High-Yield Pearls:** * **Abciximab** is a chimeric monoclonal antibody against Gp IIb/IIIa; unlike Tirofiban, its binding is non-competitive and irreversible. * **Glanzmann Thrombasthenia** is a congenital bleeding disorder caused by a deficiency or dysfunction of the Gp IIb/IIIa receptor. * **Monitoring:** Unlike Heparin (aPTT) or Warfarin (PT/INR), Gp IIb/IIIa inhibitors do not require routine coagulation monitoring, but platelet counts should be checked to monitor for drug-induced thrombocytopenia.

Practice by Chapter

Hematopoietic Growth Factors

Practice Questions

Iron Preparations and Management of Iron Deficiency

Practice Questions

Vitamin B12 and Folic Acid

Practice Questions

Anticoagulants: Heparins and Direct Inhibitors

Practice Questions

Oral Anticoagulants

Practice Questions

Antiplatelet Drugs

Practice Questions

Thrombolytic Agents

Practice Questions

Hemostatic Drugs

Practice Questions

Plasma Expanders

Practice Questions

Blood Transfusion and Alternatives

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free